BioMarin Pharmaceutical, Inc.

105 Digital Dr , Novato, CA 94949

Public
Healthcare & Pharmaceuticals - Biotechnology
around $100 - 500M
around 1K - 5K
(415) 506-6700
(415) 382-7889


BioMarin Pharmaceutical Inc. (BioMarin) develops and commercializes pharmaceuticals for various diseases and medical conditions. The Company's product portfolio consists of approximately five approved products, and multiple clinical and pre-clinical product candidates. Its approved products include Vimizim (elosulfase alpha), Naglazyme (galsulfase), Kuvan (sapropterin dihydrochloride), Aldurazyme (laronidase) and Firdapse (amifampridine phosphate). Its products in clinical development include Kyndrisa, Pegvaliase, Reveglucosidase alfa, Vosoritide (formerly BMN 111), Cerliponase alfa, BMN 044, BMN 045, BMN 053 and BMN 270. Vimizim is an enzyme replacement therapy for the treatment of mucopolysaccharidosis type IV (MPS IV A). Naglazyme is a recombinant form of N-acetylgalactosamine 4-sulfata... (Source: SEC reports)


Brand Quality - 1/2
Do you believe in BioMarin Pharmaceutical, Inc.'s mission?


Result Not Found.


No Data to Display.

246 Contacts at this company
Omar Craviotto
Manager, QA Validation
Justin Sims
Sr. Manager QA Operations
Chris Russell
Staff Scientist
Roger Lawrence
Sr. Scientist
Nymma Shemirani
Associate Manager, Regulatory Project ...
Shannon Utter
Senior Director, QA CMO
Kathie Ward
Associate Director, Meetings & Conventions ...
Mairead Singleton
Senior Technical Manager, QA ...
Lydia Hemphill
Senior Manager, Technical Operations ...

Sep 14, 2017 21:36:47
SAN RAFAEL, Calif., Sept. 14, 2017 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (Nasdaq:   BMRN) today announced that the U.S. Food and Drug Administration (FDA) has provided the company [...]

Sep 6, 2017 21:37:02
SAN RAFAEL, Calif., Sept. 6, 2017 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) announced today that it presented interim data from the dose escalation arm of a Phase 1/2 [...]

Aug 29, 2017 21:37:30
SAN RAFAEL, Calif., Aug. 29, 2017 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) today announced that the U.S. Food and Drug Administration (FDA) has accepted for Priority Review [...]

Jun 30, 2017 21:37:30
SAN RAFAEL, Calif., June 30, 2017 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) announced that the company submitted a Biologics License Application (BLA) on Friday, June 30, 2017 to [...]

Get Started Today : Sign up in 20 seconds
Search with 20+ criteria.
Export results in seconds.
Bad emails?
No worry, we give two extras for every bad email.